| Name | Title | Contact Details |
|---|
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).
Agadia is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Douglas Laboratories is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aptalis Pharma is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Valcour Strategic Group is a Peru, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.